BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Guiotto C, Italia A, Lavagna A, Rigazio C, Cosimato M, Ercole E, Mendolaro M, Rocca R, Daperno M. Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation. Digestive and Liver Disease 2019;51:1117-22. [DOI: 10.1016/j.dld.2019.05.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bezzio C, Festa S, Zerboni G, Papi C, Manes G, Saibeni S. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. Expert Opinion on Drug Safety 2018;17:437-44. [DOI: 10.1080/14740338.2018.1442432] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019;68:1688-700. [DOI: 10.1136/gutjnl-2018-317977] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
4 Caprioli F, Daperno M, Bravatà I, Brigido A, Frigerio D, Secchi O, Rispo A. Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. Eur J Gastroenterol Hepatol 2021;33:1082-90. [PMID: 34213505 DOI: 10.1097/MEG.0000000000002183] [Reference Citation Analysis]
5 Lightner AL, Mckenna NP, Tse CS, Raffals LE, Loftus EV, Mathis KL. Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. Aliment Pharmacol Ther 2018;47:573-80. [DOI: 10.1111/apt.14459] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
6 Fascì-Spurio F, Meucci G, Papi C, Saibeni S; IG-IBD (Italian Group for Inflammatory Bowel Disease). The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey. Dig Liver Dis 2017;49:1092-7. [PMID: 28801181 DOI: 10.1016/j.dld.2017.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
7 Johnston A, Natarajan S, Hayes M, MacDonald E, Shorr R. Accelerated induction regimens of TNF-alpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol. BMJ Open 2018;8:e019909. [PMID: 29382683 DOI: 10.1136/bmjopen-2017-019909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
9 Rizzello F, Mazza M, Salice M, Calabrese C, Calafiore A, Campieri M, Gionchetti P. The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. Expert Opinion on Drug Safety 2018;17:963-9. [DOI: 10.1080/14740338.2018.1510914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Pérez de Arce E, Quera R, Quigley EMM. The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Gastroenterol Clin North Am 2021;50:689-711. [PMID: 34304795 DOI: 10.1016/j.gtc.2021.03.008] [Reference Citation Analysis]
11 Sako M, Yoshimura N, Sonoda A, Okano S, Ueda M, Tezuka M, Mine M, Yamanishi S, Hashimoto K, Kobayashi K, Takazoe M, Fukata M. Safety Prediction of Infants Born to Mothers with Crohn's Disease Treated with Biological Agents in the Late Gestation Period. J Anus Rectum Colon 2021;5:426-32. [PMID: 34746508 DOI: 10.23922/jarc.2021-021] [Reference Citation Analysis]
12 Imperatore N, Foggia M, Patturelli M, Rispo A, Calabrese G, Testa A, Pellegrini L, Tosone G, Di Luna I, Nardone OM, Ricciolino S, Castiglione F. Treatment-based risk stratification of infections in inflammatory bowel disease: A comparison between anti-tumor necrosis factor-α and nonbiological exposure in real-world setting. J Gastroenterol Hepatol 2021;36:1859-68. [PMID: 33283312 DOI: 10.1111/jgh.15367] [Reference Citation Analysis]
13 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-López VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020:jjaa161. [PMID: 33026087 DOI: 10.1093/ecco-jcc/jjaa161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
14 Macaluso FS, Cottone M, Orlando A. Risk of Pneumonia Caused by Pneumocystis jiroveci in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. Clinical Gastroenterology and Hepatology 2019;17:571-2. [DOI: 10.1016/j.cgh.2017.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
15 Kuriyama A, Jackson JL. Defining metronidazole-induced encephalopathy. J Neurol 2019;266:1272-3. [PMID: 30863892 DOI: 10.1007/s00415-019-09275-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Nardelli S, Pisani LF, Tontini GE, Vecchi M, Pastorelli L. MMX® technology and its applications in gastrointestinal diseases. Therap Adv Gastroenterol 2017;10:545-52. [PMID: 28804515 DOI: 10.1177/1756283X17709974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Guillo L, D'Amico F, Achit H, Ayav C, Guillemin F, Danese S, Frimat L, Peyrin-Biroulet L. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. Dig Liver Dis 2021;53:691-6. [PMID: 33563584 DOI: 10.1016/j.dld.2021.01.015] [Reference Citation Analysis]
18 Mezzina N, Campbell Davies SE, Ardizzone S. Nonbiological therapeutic management of ulcerative colitis. Expert Opinion on Pharmacotherapy 2018;19:1747-57. [DOI: 10.1080/14656566.2018.1525361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
19 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
20 Pagliari D, Gambassi G, Piccirillo CA, Cianci R. The Intricate Link among Gut "Immunological Niche," Microbiota, and Xenobiotics in Intestinal Pathology. Mediators Inflamm 2017;2017:8390595. [PMID: 29118468 DOI: 10.1155/2017/8390595] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
21 Regmi S, Pathak S, Nepal MR, Shrestha P, Park J, Kim JO, Yong CS, Choi D, Chang J, Jeong TC, Orive G, Yook S, Jeong J. Inflammation-triggered local drug release ameliorates colitis by inhibiting dendritic cell migration and Th1/Th17 differentiation. Journal of Controlled Release 2019;316:138-49. [DOI: 10.1016/j.jconrel.2019.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
22 Cury DB, Oliveira R, Cury MS. Inflammatory bowel diseases: time of diagnosis, environmental factors, clinical course, and management - a follow-up study in a private inflammatory bowel disease center (2003-2017). J Inflamm Res 2019;12:127-35. [PMID: 31213873 DOI: 10.2147/JIR.S190929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
23 Zhou YF, Sun N, Cheng SR, Deng XD, Ye XY, Li ZJ, Zhou J, Xu GX, Qu YZ, Huang LY, Sun RR, Liang FR. Effectiveness and safety of acupuncture therapy for inflammatory bowel disease: a protocol of systematic review and meta-analysis. BMJ Open 2021;11:e045090. [PMID: 34429304 DOI: 10.1136/bmjopen-2020-045090] [Reference Citation Analysis]
24 Roberti R, Iannone LF, Palleria C, De Sarro C, Spagnuolo R, Barbieri MA, Vero A, Manti A, Pisana V, Fries W, Trifirò G, Naturale MD, Larussa T, De Francesco AE, Bosco V, Donato di Paola E, Citraro R, Luzza F, Bennardo L, Rodinò S, Doldo P, Spina E, Russo E, De Sarro G. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin 2020;36:1457-63. [PMID: 32573307 DOI: 10.1080/03007995.2020.1786681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
25 Bonfanti E, Bracco C, Biancheri P, Falcetta A, Badinella Martini M, Melchio R, Fenoglio L. Fever During Anti-integrin Therapy: New Immunodeficiency. Eur J Case Rep Intern Med 2020;7:001288. [PMID: 32206635 DOI: 10.12890/2020_001288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Daperno M, Armuzzi A, Danese S, Fries W, Liguori G, Orlando A, Papi C, Principi M, Rizzello F, Viscido A, Gionchetti P. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterol Res Pract 2019;2019:3108025. [PMID: 31565051 DOI: 10.1155/2019/3108025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
27 Regmi S, Seo Y, Ahn JS, Pathak S, Acharya S, Nguyen TT, Yook S, Sung JH, Park JB, Kim JO, Young CS, Kim HS, Jeong JH. Heterospheroid formation improves therapeutic efficacy of mesenchymal stem cells in murine colitis through immunomodulation and epithelial regeneration. Biomaterials 2021;271:120752. [PMID: 33730631 DOI: 10.1016/j.biomaterials.2021.120752] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]